Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krina Patel

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
Hepatology International|December 8, 2022
Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodiesChia-Yu Chiu, Krina Patel, Sheeba K Thomas, et al.
International Journal of Cancer|May 2, 2008
Tumoricidal activity of high-dose tumor necrosis factor-alpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdownChandrakala Menon, Todd W Bauer, Scott T Kelley, et al.
Hematological Oncology|November 11, 2021
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantationSairah Ahmed, Qiuhong Zhao, Walter Hanel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2020
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective StudyChutima Kunacheewa, Hans C Lee, Krina Patel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning RegimensHossein Maymani, Paul Lin, Rima M Saliba, et al.
American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.
European Journal of Haematology|January 17, 2016
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvementTalha Badar, Amanda Megan Cornelison, Nina D Shah, et al.
Nature Communications|February 19, 2022
ATF-4 and hydrogen sulfide signalling mediate longevity in response to inhibition of translation or mTORC1Cyril Statzer, Jin Meng, Richard Venz, et al.
The Lancet. Haematology|February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trialMichel Delforge, Krina Patel, Laurie Eliason, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
Hepatology International|December 8, 2022
Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodiesChia-Yu Chiu, Krina Patel, Sheeba K Thomas, et al.
International Journal of Cancer|May 2, 2008
Tumoricidal activity of high-dose tumor necrosis factor-alpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdownChandrakala Menon, Todd W Bauer, Scott T Kelley, et al.
Hematological Oncology|November 11, 2021
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantationSairah Ahmed, Qiuhong Zhao, Walter Hanel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2020
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective StudyChutima Kunacheewa, Hans C Lee, Krina Patel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning RegimensHossein Maymani, Paul Lin, Rima M Saliba, et al.
American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.
European Journal of Haematology|January 17, 2016
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvementTalha Badar, Amanda Megan Cornelison, Nina D Shah, et al.
Nature Communications|February 19, 2022
ATF-4 and hydrogen sulfide signalling mediate longevity in response to inhibition of translation or mTORC1Cyril Statzer, Jin Meng, Richard Venz, et al.
The Lancet. Haematology|February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trialMichel Delforge, Krina Patel, Laurie Eliason, et al.
Pageof 8